Novo Nordisk A/S announced a share repurchase program initiated on November 11, 2024, with a budget of DKK 20 billion spanning 12 months. As of December 6, 2024, the company has repurchased 21,818,078 B shares at an average price of DKK 828.33 per share, valued at DKK 18 billion.